2023 Yields Several Promising Trial Updates in dMMR/pMMR End

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

Related Keywords

Pennsylvania , United States , Texas , Houston , West Penn , Shannonn Westin , Eirwenm Miller , Christopherb Morse , , Allegheny Health Network , University Of Texas Md Anderson Cancer Center , European Society For Medical Oncology , Society Of Gynecologic Oncology Annual Meeting , European Society , Medical Oncology , Science Summit , Allegheny Health Network West Penn Hospital , Allegheny Health , Gynecologic Oncology Annual Meeting , Cancer Center , Endometrial Cancer , Dmmr , Pmmr , Duoe Trial , Nrg Gy018 Trial , Ruby Trial , Attend Trial , D ,